The elevated incidence of drug-induced ILD among those who received an mTOR inhibitor combined with trastuzumab is consistent with previous studies demonstrating associations between mTOR inhibitors and ILD among cancer patients [10, 36]. This evidence concerns the gene MTOR and cancer.